INS and type 2 diabetes mellitus: Although pharmacological therapies for prevention of T2D have not yet been recommended by the American Diabetes Association [59] and have not been approved by the U.S. Food and Drug Administration, insulin-sensitizing agents have been found to reduce T2D risk by 31–77% [65].